Neurogene Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President of Clinical Development

Dr. Huttner to lead clinical development as Neurogene advances towards first Investigational New Drug (IND) filing

NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded with a mission to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced Kenneth Huttner, M.D., Ph.D., has joined the company as Senior Vice President of Clinical Development, reporting to Effie Albanis M.D., Neurogene’s Chief Medical Officer. Dr. Huttner is a seasoned clinical expert with more than 15 years of experience leading clinical development programs in small and large biopharmaceutical companies. Dr. Huttner’s deep knowledge and expertise regarding translational medicine, orphan disease and gene therapy will enable him to play an integral role in leading Neurogene’s portfolio of gene therapy programs into the clinic.

“I am very excited to be joining Neurogene and supporting its focus on gene therapy for patients living with devastating neurological disorders,” said Kenneth Huttner, M.D., Ph.D. “In a field with significant unmet medical need, I look forward to working for the benefit of children and their families, who are in urgent need of novel therapeutic approaches.”

Dr. Huttner received his M.D. and Ph.D. from Yale University and completed his clinical training in Pediatrics, Neonatology and Clinical Genetics at the National Institute of Child Health and Human Development (NICHD). He began his career in the pharmaceutical industry more than 15 years ago, taking on increasing responsibility across small and large pharmaceutical companies, including Novartis, Bioverativ and, most recently, LogicBio. He has led clinical development programs within numerous therapeutic areas and modalities with a special emphasis on pediatric populations.

“We are thrilled to have Dr. Kenneth Huttner join our team. Ken’s significant leadership and clinical development experience, as well as his background in neonatal intensive care and clinical genetics, will enable us to successfully grow our organization and implement a comprehensive clinical strategy as we move toward the clinic,” said Effie Albanis, M.D., Neurogene’s Chief Medical Officer.

About Neurogene Inc.

Neurogene Inc. is focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs are designed to use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy. For more information, visit www.neurogene.com.